Search fresh public links, source activity, and ready-to-use post angles for Gsk.
Fresh curated links around GSK are collected here so marketers can spot useful updates and turn timely ideas into posts faster.
Recent items include:
Recent curated links from global sources. Generate one free draft from any story, then use SocialBu to schedule and refine your content calendar.
GSK is handing over $110 million upfront to Hutchmed in a deal worth up to $1.295 billion to get its hands on a first-in-class oncology candidate.
With its latest foray into China, GSK acquired rights from Hutchmed to an “antibody-targeted therapy conjugate” impacting two well-known cancer drivers, EGFR and KRAS.
Pharmaceuticals company is investing £400m in UK life sciences and moving scientists to new Cambridge R&D siteBusiness live – latest updatesThe British drugmaker GSK is to anno...
Drugs giant GSK saw its shares drift lower despite announcing progress on two key products yesterday.
Mixed Phase 3 data for camlipixant prompted the British pharma to cease development, making the drug the third from its class to fail.
GSK has unveiled an ambitious three-year plan to divert resources to its late-stage R&D programs and shift its research headquarters—but CEO Luke Miels is being tight-lipped ab...
The clearance is GSK’s first for a lung cancer medicine and the latest step forward in a yearslong push by the British drugmaker into oncology.
GSK gained rights to a Hutchmed antibody-targeted therapy conjugate, or ATTC. This new type of targeted therapy blocks two cancer-driving proteins and will initially be developed f...
GSK has linked its mRNA seasonal flu vaccine candidate to higher immune responses than conventional jabs in a phase 2 trial, emboldening the company to start a pivotal study this m...
Pharmaceutical company’s move to new £400m research centre accompanied by encouraging news for shareholders“A vote of confidence in British business,” trumpeted Andy Burnham, seizi...
GSK said the mixed Phase 3 results for camlipixant mean this pill “is unlikely to transform patient care” in recurrent chronic cough. GSK is stopping work in this indication, a set...
GSK has ended development of camlipixant in chronic cough after delivering mixed phase 3 data, dealing a major blow to a potential blockbuster that analysts saw as the key 2026 cat...
GSK drug Jideytro received FDA approval for treating advanced cases of non-small cell lung cancer driven by ROS1 alterations. This molecule came from Nuvalent, which GSK recently a...
GSK, led by boss Luke Miels, pictured, said it will be closing down its R&D site in Stevenage, Hertfordshire, and moving its staff to a new facility in Cambridge.
GSK is boosting its AI chops with a new deal worth up to $110 million with Relation.
GSK drug Jemperli met the main goal of a pivotal Phase 2 test in patients with a rare type of rectal cancer, paving the way for regulatory submissions. This antibody drug has alrea...
Hansoh Pharmaceutical has guided its GSK-partnered, B7-H3-directed antibody-drug conjugate to another phase 3 win in China.
The pharma hasn’t yet revealed what kind of job cuts might be involved in the plan, which will help it absorb the coming loss of patents important to its HIV drug franchise.
GSK’s messenger RNA vaccine for seasonal influenza is designed to prompt an immune response to two proteins on the surface of the virus. That could be an advantage over Moderna’s r...
Use SocialBu to discover ideas, generate post drafts, and schedule them across your social channels.